PCI Pharma Expands Analytical Capabilities
The contract service provider will invest in a laboratory expansion at its site located in Tredegar, Wales, UK.
Contract service provider PCI Pharma Services announced on March 21, 2018 that it will invest in a laboratory expansion at its site located in Tredegar, Wales, UK.
According to the company, the investment will support an approximately 60% increase in analyst capacity and a more than 20% increase in high-performance liquid chromatography capacity as well as triple its capacity for sample receipt.
The Tredegar facility is the company’s center of excellence for the development and manufacturing of pharmaceutical products in a variety of dosage forms and specializes in the processing of highly potent molecules. The facility uses contained technology such as Xcelodose micro-dosing for early stage development drug-in-capsule, fluid bed granulation, and roller compaction for products sensitive to heat and moisture.
PCI states the layout design of the facility incorporates Lean philosophies and optimized safety, combined with leading ergonomic principles, to deliver enhanced throughput and additional efficiency improvements.
“Expansion of our laboratory services is an important program for the Tredegar site. Speed to market is of critical importance to our clients. We pride ourselves on continually improving our service for both existing and potential new clients and our analytical service is integral from the early stages of analytical development through to commercial launch and the associated annual stability testing,” said Richard Yarwood, senior vice president, PCI Pharma Services, in a company press release.
Source: PCI
